Unique immune and inflammatory cytokine profiles may define long COVID syndrome

Clin Exp Med. 2023 Oct;23(6):2925-2930. doi: 10.1007/s10238-023-01065-6. Epub 2023 Apr 16.

Abstract

Purpose: Long COVID is estimated to occur in 5-10% of individuals after acute SARS-CoV-2 infection. However, the pathophysiology driving the disease process is poorly understood.

Methods: We evaluated urine and plasma inflammatory and immune cytokine profiles in 33 individuals with long COVID compared to 33 who were asymptomatic and recovered, and 34 without prior infection.

Results: Mean urinary leukotriene E4 was significantly elevated among individuals with long COVID compared to asymptomatic and recovered individuals (mean difference 774.2 pg/mL; SD 335.7) and individuals without prior SARS-CoV-2 infection (mean difference 503.1 pg/ml; SD 467.7). Plasma chemokine ligand 6 levels were elevated among individuals with long COVID compared to individuals with no prior SARS-CoV-2 infection (mean difference 0.59 units; SD 0.42). We found no significant difference in angiotensin-converting enzyme 2 antibody levels. Plasma tumor necrosis factor receptor-associated factor 2 (TRAF2) levels were reduced among individuals with long COVID compared to individuals who were asymptomatic and recovered (mean difference = 0.6 units, SD 0.46). Similarly, the mean level of Sarcoma Homology 2-B adapter protein 3 was 3.3 units (SD 1.24) among individuals with long COVID, lower than 4.2 units (SD 1.1) among individuals with recovered, asymptomatic COVID.

Conclusion: Our findings suggest that further studies should be conducted to evaluate the role of leukotriene E4 as a potential biomarker for a diagnostic test. Furthermore, based on reductions in TRAF2, long COVID may be driven in part by impaired TRAF2-dependent immune-mediated inflammation and potentially immune exhaustion.

Keywords: Antibodies; Biomarkers; Inflammatory cytokines; Long COVID; SARS-CoV-2.

Publication types

  • Letter

MeSH terms

  • COVID-19*
  • Cytokines
  • Humans
  • Leukotriene E4
  • Post-Acute COVID-19 Syndrome*
  • SARS-CoV-2
  • TNF Receptor-Associated Factor 2
  • Ubiquitin-Protein Ligases

Substances

  • Leukotriene E4
  • TNF Receptor-Associated Factor 2
  • Ubiquitin-Protein Ligases
  • Cytokines